'Breakthrough' mRNA cancer drug shows success in curbing melanoma tumours
US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the recurrence of melanoma tumours in a late-stage trial hailed by experts as a "breakthrough".
The news sent shares in Moderna soaring 145 percent to USD 154 while Merck's stock was up more than 12 percent to USD 152.
The drug, called "intismeran autogene," is based on the same messenger RNA (mRNA) technology behind Covid-19 vaccines.
Researchers have for years been trying to apply mRNA treatments against cancer, but this was the first time such a drug showed positive results in a large, late-stage clinical trial.
"Today marks an extraordinary milestone for Moderna, for mRNA science and, most importantly, for patients with cancer," Moderna CEO Stephane Bancel said in a statemen...

